Guardion Health Sciences Names Dr. David Evans as Interim President and Interim Chief Executive Officer
June 15 2020 - 4:20PM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI) announced today that its Board of Directors has
appointed Dr. David Evans, Ph.D. as the Company's Interim President
and Interim Chief Executive Officer effective immediately. Dr.
Evans has served as the Company’s Chief Science Officer and was the
founder of the Company’s subsidiary, VectorVision. Dr. Evans joined
the Guardion Board of Directors effective with the Company’s
acquisition of VectorVision on September 29, 2017.
David Evans succeeds Michael Favish, who is the
founder of Guardion and who is stepping down as an officer and
employee of Guardion and is also leaving the Board of Directors of
Guardion.
Dr. Evans commented, “The Board of Directors
would like to thank Mr. Favish for his leadership and service to
Guardion for these past years.”
Dr. Evans continued, “Guardion has successfully
raised much needed capital and strengthened the Company’s balance
sheet through the Company’s initial public offering and follow-on
public offerings in 2019, and is now focusing on refining and
executing its business plan in order to effectively deploy its
capital, improve the financial and operational performance of its
business units, and enhance long-term stockholder value.”
The Board is conducting an extensive search to
identify the Company’s next Chief Executive Officer and will
provide additional information to shareholders as it becomes
available.
About Guardion Health Sciences, Inc.
Guardion is a specialty health sciences company
(i) that develops medical foods and medical devices in the ocular
health marketplace and (ii) that is developing nutraceuticals that
the Company believes will provide medicinal and health benefits to
consumers. Information and risk factors with respect to Guardion
and its business, including its ability to successfully develop and
commercialize its proprietary products and technologies, may be
obtained in the Company’s filings with the SEC at www.sec.gov.
About VectorVision®
VectorVision® specializes in the standardization
of contrast sensitivity, glare sensitivity, low contrast acuity,
and ETDRS acuity vision testing. Its patented standardization
system provides the practitioner or researcher the ability to
delineate very small changes in visual capability, either as
compared to the population or from visit to visit. VectorVision’s®
patented technology is considered the standard of care for clinical
trials. VectorVision® is a wholly owned subsidiary of Guardion.
Guardion has completed development of the
proprietary VectorVision® CSV-2000 standardized contrast
sensitivity test and recently introduced the commercial product to
the marketplace. The CSV-2000 is the only computer-generated vision
testing instrument available that will provide the optical
marketplace with the Company’s proprietary, industry-standard
contrast sensitivity test, along with a full suite of standard
vision testing protocols. The proprietary standardization
methodology incorporated into the CSV-2000 includes a patented
technology known as AcQviz that automatically and constantly
measures and adjusts screen luminance to a fixed standard light
level for vision testing.
Forward-Looking Statement Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but not limited to, the Company’s ability to
raise sufficient financing to implement its business plan, the
impact of the COVID-19 pandemic on the Company’s business,
operations and the economy in general, and the Company’s ability to
successfully develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward- looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Relations Contact:
Porter, LeVay & Rose, Inc.
Michael PorterTelephone: (212) 564-4700 E-mail:
mike@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024